Related Experiment Video

Updated: Jun 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia

Paul La Rosée1, Andreas Hochhaus

  • 1Klinik für Innere Medizin II, Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany.

Current Opinion in Hematology
|January 15, 2010
PubMed
Abstract

Insights

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia is complex, involving mutations and other mechanisms. Understanding these pathways is key to developing new treatments and preventing disease progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Resistance to tyrosine kinase inhibitors (TKIs) like imatinib, nilotinib, and dasatinib is a major challenge in chronic myeloid leukemia (CML) treatment.
  • While ABL-kinase domain mutations explain some resistance, approximately 50% of cases involve unknown, mutation-independent mechanisms.

Purpose of the Study:

  • To review recent publications on molecular mechanisms driving clinical resistance to TKIs in CML.
  • To explore mutation-independent resistance pathways and their clinical implications.

Main Methods:

  • Literature review of preclinical and clinical studies on TKI resistance in CML.
  • Analysis of data on the efficacy of second-line TKIs (dasatinib, nilotinib) in patients with pre-existing mutations.
  • Investigation of emerging resistance mechanisms and potential therapeutic strategies.

Main Results:

  • Second-line TKIs demonstrate efficacy consistent with in vitro predictions for patients with specific kinase mutations.
  • New insights into multifactorial, mutation-independent resistance mechanisms have been uncovered.
  • Preclinical and clinical data suggest interferon-alpha may be a valuable adjunct to TKI therapy.
  • The necessity of continuous kinase inhibition for optimal efficacy is being re-evaluated.

Conclusions:

  • Understanding the complexity of TKI resistance is crucial for preventing treatment failure in CML.
  • Current clinical research focuses on optimizing TKI therapy through dose adjustments, scheduling, novel inhibitors, and combination strategies to overcome resistance.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...